<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="iso-abbrev">Braz J Cardiovasc Surg</journal-id><journal-id journal-id-type="publisher-id">rbccv</journal-id><journal-title-group><journal-title>Brazilian Journal of Cardiovascular Surgery</journal-title></journal-title-group><issn pub-type="ppub">0102-7638</issn><issn pub-type="epub">1678-9741</issn><publisher><publisher-name>Sociedade Brasileira de Cirurgia Cardiovascular</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">30916121</article-id><article-id pub-id-type="pmc">6436776</article-id><article-id pub-id-type="doi">10.21470/1678-9741-2018-0336</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Benefits of Fasting Abbreviation with Carbohydrates and Omega-3
Infusion During CABG: a Double-Blind Controlled Randomized Trial</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1132-9667</contrib-id><name><surname>Feguri</surname><given-names>Gibran Roder</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="c1"/><role>MD, PhD</role></contrib><contrib contrib-type="author"><name><surname>de Lima</surname><given-names>Paulo Ruiz L&#x000fa;cio</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Franco</surname><given-names>Anna Carolina</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Cruz</surname><given-names>Felipe Ramos Honorato De La</given-names></name><xref ref-type="aff" rid="aff2">2</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Borges</surname><given-names>Danilo Cerqueira</given-names></name><xref ref-type="aff" rid="aff1">1</xref><role>MD</role></contrib><contrib contrib-type="author"><name><surname>Toledo</surname><given-names>Laura Ramos</given-names></name><xref ref-type="aff" rid="aff3">3</xref><role>PT</role></contrib><contrib contrib-type="author"><name><surname>Segri</surname><given-names>Neuber Jos&#x000e9;</given-names></name><xref ref-type="aff" rid="aff4">4</xref><role>PhD</role></contrib><contrib contrib-type="author"><name><surname>de Aguilar-Nascimento</surname><given-names>Jos&#x000e9; Eduardo</given-names></name><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="aff" rid="aff6">6</xref><role>MD, PhD</role></contrib></contrib-group><aff id="aff1">
<label>1</label> Department of Cardiology and Cardiovascular Surgery, Hospital Geral
Universit&#x000e1;rio, Universidade de Cuiab&#x000e1; (HGU-UNIC), Cuiab&#x000e1;, MT,
Brazil.</aff><aff id="aff2">
<label>2</label> Department of Cardiovascular Surgery, Hospital Geral
Universit&#x000e1;rio, Universidade de Cuiab&#x000e1; (HGU-UNIC), Cuiab&#x000e1;, MT,
Brazil.</aff><aff id="aff3">
<label>3</label> Department of Physical Therapy, Hospital Geral
Universit&#x000e1;rio, Universidade de Cuiab&#x000e1; (HGU-UNIC), Cuiab&#x000e1;, MT,
Brazil.</aff><aff id="aff4">
<label>4</label> Department of Statistics, Universidade Federal do Mato Grosso
(UFMT), Cuiab&#x000e1;, MT, Brazil.</aff><aff id="aff5">
<label>5</label> Universidade Federal do Mato Grosso (UFMT), Cuiab&#x000e1;, MT,
Brazil.</aff><aff id="aff6">
<label>6</label> Universidade de V&#x000e1;rzea Grande (UNIVAG), V&#x000e1;rzea
Grande, MT, Brazil.</aff><author-notes><corresp id="c1">Correspondence Address: <bold>Gibran Roder Feguri</bold>,
http://orcid.org/0000-0002-1132-9667, Rua Sen. Filinto Muller 1588/704,
Cuiab&#x000e1;, MT, Brazil - Zip code: 78045-395. Email:
<email>gibranrf@yahoo.com.br</email></corresp></author-notes><pub-date pub-type="epub-ppub"><season>Mar-Apr</season><year>2019</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><season>Mar-Apr</season><year>2019</year></pub-date><volume>34</volume><issue>2</issue><fpage>125</fpage><lpage>135</lpage><history><date date-type="received"><day>22</day><month>10</month><year>2018</year></date><date date-type="accepted"><day>31</day><month>10</month><year>2018</year></date></history><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an Open Access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is
properly cited.</license-p></license></permissions><abstract><sec><title>Objective</title><p>To assess postoperative clinical data considering the association of
preoperative fasting with carbohydrate (CHO) loading and intraoperative
infusion of omega-3 polyunsaturated fatty acids (&#x003c9;-3 PUFA).</p></sec><sec><title>Methods</title><p>57 patients undergoing coronary artery bypass grafting (CABG) were randomly
assigned to receive 12.5% maltodextrin (200 mL, 2 h before anesthesia),
(CHO, n=14); water (200 mL, 2 h before anesthesia), (control, n=14); 12.5%
maltodextrin (200 mL, 2 h before anesthesia) plus intraoperative infusion of
&#x003c9;-3 PUFA (0.2 g/kg), (CHO+W3, n=15); or water (200 mL, 2 h before
anesthesia) plus intraoperative infusion of &#x003c9;-3 PUFA (0.2 g/kg), (W3,
n=14). The need for vasoactive drugs was analyzed, in addition to
postoperative inflammation and metabolic control.</p></sec><sec><title>Results</title><p>There were two deaths (3.5%). Patients in CHO groups presented a lower
incidence of hospital infection (RR=0.29, 95% CI 0.09-0.94;
<italic>P</italic>=0.023), needed fewer vasoactive drugs during surgery
and ICU stay (<italic>P</italic>&#x0003c;0.05); and had better blood glucose
levels in the first six hours of recovery (<italic>P</italic>=0.015),
requiring less exogenous insulin (<italic>P</italic>=0.018). Incidence of
postoperative atrial fibrillation (POAF) varied significantly among groups
(<italic>P</italic>=0.009). Subjects who receive &#x003c9;-3 PUFA groups
had fewer occurrences of POAF (RR=4.83, 95% CI 1.56-15.02;
<italic>P</italic>=0.001). Patients in the W3 group had lower
ultrasensitive-CRP levels at 36 h postoperatively
(<italic>P</italic>=0.008). Interleukin-10 levels varied among groups
(<italic>P</italic>=0.013), with the highest levels observed in the
postoperative of patients who received intraoperative infusion of &#x003c9;-3
PUFA (<italic>P</italic>=0.049).</p></sec><sec><title>Conclusion</title><p>Fasting abbreviation with carbohydrate loading and intraoperative infusion of
&#x003c9;-3 PUFA is safe and supports faster postoperative recovery in
patients undergoing on-pump CABG.</p></sec></abstract><kwd-group><kwd>Myocardial Revascularization</kwd><kwd>Perioperative Care</kwd><kwd>Atrial Fibrillation</kwd><kwd>Inflammation</kwd><kwd>Hyperglycemia</kwd></kwd-group><funding-group><award-group><funding-source>CNPq</funding-source><award-id>472881/2011-6</award-id><award-id>301631/2015-8</award-id></award-group><funding-statement>We received partial financial support from CNPq (Conselho
Nacional de Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico - "National
Council for Scientific and Technological Development" of Brazil). CNPq Processes
472881/2011-6 e 301631/2015-8.</funding-statement></funding-group></article-meta></front><body><table-wrap id="t4" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="42%" span="1"/><col width="5%" span="1"/><col width="5%" span="1"/><col width="42%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" style="background-color:#e6e7e8" rowspan="1">Abbreviations,
acronyms &#x00026; symbols</th><th align="center" rowspan="1" colspan="1">&#x000a0;</th><th align="center" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th><th align="center" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x000a0;</th></tr></thead><tbody><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ACERTO</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= ACElera&#x000e7;&#x000e3;o
da Recupera&#x000e7;&#x000e3;o TOtal P&#x000f3;s-operat&#x000f3;ria</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CRP</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= C-reactive protein</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">AMI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Acute myocardial
infarction</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CVA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cerebrovascular
accident</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ANOVA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Analysis of
variance</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">ICU</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Intensive care unit</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">BMI</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Body mass index</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">LVEF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Left ventricular
ejection fraction</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CABG</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery bypass
grafting</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">POAF</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Postoperative atrial
fibrillation</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CAD</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Coronary artery
disease</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SGA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Subjective global
assessment</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CC</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cross-clamp</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">SIRS</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Systemic inflammatory
response syndrome</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CHO</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Carbohydrate</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">W3</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Group W3</td></tr><tr><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">CPB</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Cardiopulmonary
bypass</td><td align="left" rowspan="1" colspan="1">&#x000a0;</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">&#x003c9;-3 PUFA</td><td align="left" style="background-color:#e6e7e8" rowspan="1" colspan="1">= Omega-3 polyunsaturated
fatty acids</td></tr></tbody></table></table-wrap><sec sec-type="intro"><title>INTRODUCTION</title><p>Advances in medicine and questioning of obsolete practices have led to a search for
factors that could improve the quality of healthcare and minimize errors. For this
purpose, surgical services have created multiprofessional and multidisciplinary
teams and established fast-track and checklist protocols to determine perioperative
care associated with lower morbidity and mortality, reduced costs, and faster
postoperative recovery<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup>.</p><p>The ACERTO Project (<italic>ACElera&#x000e7;&#x000e3;o da Recupera&#x000e7;&#x000e3;o
TOtal P&#x000f3;s-operat&#x000f3;ria</italic>) is an example of a national
multimodal protocol aimed at accelerating postoperative recovery of patients. The
basis for this protocol include the abbreviation of preoperative fasting with intake
of carbohydrate-rich fluids; early postoperative feeding and mobility; reduced
length of stay in the intensive care unit (ICU); perioperative nutritional
assessment and therapy; rational antibiotic prophylaxis; restriction of
perioperative intravenous fluids; reduced use of drains and catheters; sedation; and
informed consent<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>]</sup>.</p><p>It is estimated that 17.5 million people die every year from cardiovascular diseases,
which represents 31% of all deaths globally. Out of those, approximately 7.4 million
(42%) are the result of coronary artery disease (CAD)<sup>[<xref rid="r4" ref-type="bibr">4</xref>]</sup>. A therapeutic option for CAD and one of the most
studied and performed surgeries in the world<sup>[<xref rid="r5" ref-type="bibr">5</xref>]</sup>, coronary artery bypass grafting (CABG) reestablishes blood
flow in obstructed coronary vessels. This procedure is largely carried out with the
support of cardiopulmonary bypass (CPB). Nevertheless, the use of CPB has been
associated with both the onset and worsening of systemic inflammatory response
syndrome (SIRS), which occurs in the postoperative period of cardiovascular surgery.
SIRS is characterized by leukocytosis, release of proinflammatory cytokines (among
other proteins in the acute phase), and increased vascular permeability, resulting
in accumulation of interstitial fluid and organic lesions mainly in the heart,
kidneys, and lungs, thereby contributing to increased operative morbidity<sup>[<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r7" ref-type="bibr">7</xref>]</sup>.</p><p>Despite being controversial, corticosteroid use can interfere with adverse effects
resulting from patient's blood going through the CPB circuit. Still, the literature
corroborates the hypothesis that it is necessary to act on several related factors
to relieve the inflammation caused by CPB<sup>[<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r8" ref-type="bibr">8</xref>]</sup>. It is in this
context that immunomodulatory drugs, such as omega-3 (&#x003c9;-3), have gained
prominence in cardiovascular surgery with promising outcomes<sup>[<xref rid="r9" ref-type="bibr">9</xref>]</sup>.</p><p>Omega-3 polyunsaturated fatty acids (&#x003c9;-3 PUFA) are directly involved in the
balance and metabolism of body fat, immunity, and postoperative immune
response<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>. Evidence
indicates that &#x003c9;-3 PUFA can be beneficial for patients undergoing
cardiovascular surgery as it acts in the postoperative inflammatory
response<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. A recent
meta-analysis showed that &#x003c9;-3 can reduce the incidence of postoperative
atrial fibrillation (POAF) as well as length of hospital stay<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. Although this type of oil can be
administered orally-because it is rapidly absorbed by cell membranes-it can also be
given intravenously, particularly for patients in the ICU and a number of surgical
procedures<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup>.</p><p>POAF is among the most common complications after CABG, with an incidence ranging
from 10% to 40%. This type of postoperative arrhythmia can interfere with the
clinical evolution of patients following CABG, leading to increased costs, higher
morbidity, longer hospital stays, and even mortality. Perioperative strategies to
mitigate POAF are highly important to cardiovascular surgery and thus are being
constantly studied<sup>[<xref rid="r13" ref-type="bibr">13</xref>,<xref rid="r14" ref-type="bibr">14</xref>]</sup>.</p><p>On the other hand, abbreviation of preoperative fasting with oral intake of
carbohydrates (CHO) can minimize insulin resistance and hyperglycemia after
cardiovascular surgery<sup>[<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r16" ref-type="bibr">16</xref>]</sup>. Moreover, it can also lower the
incidence of postoperative nausea and vomiting<sup>[<xref rid="r17" ref-type="bibr">17</xref>]</sup>. Due to its benefits, this has become a practice accepted
by several anesthesiology societies<sup>[<xref rid="r18" ref-type="bibr">18</xref>]</sup>. In particular for cardiovascular surgery, randomized studies
have shown that brief fasting with CHO intake two hours before induction of
anesthesia can minimize the need for perioperative vasoactive drugs and reduce
length of ICU and hospital stay<sup>[<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r16" ref-type="bibr">16</xref>]</sup>.</p><p>Within this framework, this study set out to assess whether abbreviation of fasting
with CHO-rich fluids associated with intraoperative infusion of &#x003c9;-3 PUFA
could interfere with postoperative morbidity, control of blood glucose and
inflammation, as well as recovery in patients undergoing on-pump CABG.</p></sec><sec sec-type="methods"><title>METHODS</title><p>This is a prospective, randomized, double-blind clinical trial, which evaluated
patients undergoing on-pump CABG at General University Hospital (Cuiab&#x000e1;/MT -
Brazil) between March 2014 and June 2016. The study was approved by the Ethics
Research Committee of Universidade de Cuiab&#x000e1; (UNIC) under CAAE No.
30493514.5.000.5165, on June 3, 2014. The study was registered on ClinicalTrials.gov
under NCT: 03017001.</p><p>Male and female patients aged between 18 and 80 years with CAD and eligible for
elective on-pump CABG were included. All patients signed an informed consent form.
Exclusion criteria included: patients under 18 years or older than 80 years; those
who did not give their informed consent; insulin-dependent diabetes; fasting blood
glucose level above 150 mg/dL; patients with gastroparesis or gastroesophageal
reflux disease; heavy use of &#x003c9;-3 PUFA or corticosteroids up to six months
prior to surgery; patients with cirrhosis of the liver (Child class A, B or C);
acute or chronic kidney injury with creatinine equal to or greater than 2.0;
patients on hemodialysis; uncontrolled dyslipidemia (triglycerides twice as high as
the reference value); previously diagnosed coagulopathy and/or platelet count lower
than the reference value; allergy to fish or shrimp; emergency surgery; reoperation;
combined surgical procedures; patients with acute coronary syndrome and mechanical
complications of myocardial infarction; subjective global assessment (SGA) class C;
any type of transfusion three months prior to surgery.</p><p>Sixty patients with CAD were included consecutively and randomly assigned (1:1) to
four groups with 15 patients each, using QuickCalcs(tm) (GraphPad Software Inc., San
Diego, CA, USA) online software. Interventions were defined as follows: 1) Control
group, brief fasting with 200 mL of water two hours before surgery; 2) CHO group,
brief fasting with oral intake of 200 mL of water with 25 g (12.5%) of maltodextrin
two hours before surgery; 3) CHO+W3 group, brief fasting with 200 mL of water with
25 g (12.5%) of maltodextrin two hours before surgery and intraoperative infusion of
0.2 g/kg of &#x003c9;-3 PUFA for four hours; and 4) W3 group, brief fasting with 200
mL of water and intraoperative infusion of 0.2 g/kg &#x003c9;-3 PUFA for four
hours.</p><p>A hospital dietitian, as the only attendant to do the charted randomization, directed
the preoperative intake. The drinks delivered by the ward nurse were given to the
patients prior to transportation to the operating room. The anesthesiologist was
also informed (by the dietician) of which patients would receive intraoperative
&#x003c9;-3 PUFA. None of the surgical team (surgeon or assistants) was aware of the
patient's assignments. A team of cardiologists and intensive care physicians, also
blind to study design and patient randomization, collected all data.</p><sec><title>Variables Analyzed</title><p>The main outcome variables analyzed in the study included: incidence of POAF;
infection; major combined cardiovascular events - acute myocardial infarction
(AMI), cerebrovascular accident (CVA), and hospital mortality; need for
vasoactive drugs in the operating room and in the ICU; blood sugar level,
monitored through capillary blood glucose serial testing; assessment of insulin
resistance based on the amount of exogenous insulin used to maintain glycemia at
&#x0003c;150 mg/dL intraoperatively and in the first six hours of recovery in the
ICU; evaluation of the inflammatory response through acute phase inflammatory
markers; ultrasensitive C-reactive protein (CRP); and interleukins 6 and 10
(IL-6 and IL-10).</p><p>The secondary outcome variables analyzed in the study included: bronchial
aspiration during induction of anesthesia; bleeding in the first 12 hours of
recovery in the ICU; perioperative use of packed red blood cells and/or blood
components; length of stay in the ICU; duration of mechanical ventilation; and
length of postoperative hospital stay.</p></sec><sec><title>Anesthesia and Surgical Technique</title><p>The same surgeon carried out all the surgical procedures. Routine anesthetic
practices were used. Induction was performed with 0.2 mL/kg etomidate infusion,
5 mcg/kg fentanyl citrate, and 0.1 mg/kg pancuronium bromide. Anesthesia was
maintained through isoflurane inhalation at a normal dose (0.6-1.8%) and, if
needed, bolus administration of 2 mcg/kg fentanyl, 0.1 mg/kg midazolam, and 0.05
mg/kg pancuronium bromide to induce muscle relaxation. Patients were kept on
mechanical ventilation with oxygen (FiO<sub>2</sub>) at 60% (or higher, as
needed).</p><p>Standard surgical technique was used, and the inlet through median sternotomy
with CPB in the allotted time. A membrane oxygenator (Braile Biom&#x000e9;dica,
S&#x000e3;o Jos&#x000e9; do Rio Preto, Brazil) was used. For myocardial
protection, hypothermic intermittent anterograde blood cardioplegia (every 15-20
min) and mild systemic hypothermia (33-35&#x000b0;C) were used. Patients received 1.5 g
of intravenous cefuroxime one hour before anesthetic induction and one
additional dose after CPB. Maintenance doses (750 mg) were administered every
six hours for 48 hours. Routine 7 mg/kg of methylprednisolone was administered
intravenously during anesthetic induction.</p></sec><sec><title>Blood Sample Collection for Analysis</title><p>Except for the first blood sample, collection was performed through the invasive
blood pressure circuit. Seven blood samples were collected at different times,
as illustrated in <xref ref-type="fig" rid="f1">Figure 1</xref>.</p><p>
<fig id="f1" orientation="portrait" position="float"><label>Fig. 1</label><caption><p>Graphical representation of seven blood samples collected for
analysis in different phases of the perioperative period.</p></caption><graphic xlink:href="rbccv-34-02-0125-g01"/></fig>
</p></sec><sec><title>Statistical Analysis</title><p>Sample calculation was performed, and every variable was submitted to the
Shapiro-Wilk test for normality before analysis. For values with Gaussian
distribution, paired or unpaired t-tests and analysis of variance (ANOVA) for
repeated measures were performed; non-parametric tests of Friedman, Wilcoxon,
Mann-Whitney, and Kruskal-Wallis were used for non-Gaussian data. Qualitative
variables were analyzed using chi-square and Fisher's exact tests. Descriptive
analyses were performed on Microsoft Office Excel 2007 (Microsoft Corp.,
Redmond, WA, USA) and statistical analyses were performed with Stata v.13.
(Stata Statistical Software: Release 13. College Station, TX: StataCorp LP,
USA). Every test was two-tailed at 80% power, with significance level set at
<italic>P</italic>&#x0003c;0.05 (&#x003b1;=5%).</p></sec></sec><sec sec-type="results"><title>RESULTS</title><p>The study design is shown in the flowchart in <xref ref-type="fig" rid="f2">Figure
2</xref>. Of the 96 eligible patients, 36 were excluded for different reasons.
The remaining 60 patients were randomly assigned into four groups. After exclusion
of one patient in each of the CHO, W3, and Control groups, 57 patients were analyzed
(CHO+W3: n=15; others: n=14).</p><p>
<fig id="f2" orientation="portrait" position="float"><label>Fig. 2</label><caption><p>Flowchart showing patient selection for the study.</p></caption><graphic xlink:href="rbccv-34-02-0125-g02"/></fig>
</p><p>Anthropometric data per group are shown in <xref rid="t1" ref-type="table">Table
1</xref> and clinical data, in <xref rid="t2" ref-type="table">Table 2</xref>.
Analyses of the variables listed in the aforementioned tables showed that the groups
are homogenous.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><p>Demographic and anthropometric data of 57 patients undergoing on-pump
CABG.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">CHO<break/>(n=14)</th><th align="center" rowspan="1" colspan="1">Control<break/>(n=14)</th><th align="center" rowspan="1" colspan="1">CHO+W3<break/>(n=15)</th><th align="center" rowspan="1" colspan="1">W3<break/>(n=14)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age (years)</td><td align="center" rowspan="1" colspan="1">60.86&#x000b1;10.55 (63)</td><td align="center" rowspan="1" colspan="1">63.43&#x000b1;8.56 (63.50)</td><td align="center" rowspan="1" colspan="1">59.93&#x000b1;11.77 (63)</td><td align="center" rowspan="1" colspan="1">62.71&#x000b1;10.90 (65)</td><td align="center" rowspan="1" colspan="1">0.797<sup><xref ref-type="table-fn" rid="TFN1">A</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Males</td><td align="center" rowspan="1" colspan="1">12 (86)</td><td align="center" rowspan="1" colspan="1">10 (71)</td><td align="center" rowspan="1" colspan="1">7 (47)</td><td align="center" rowspan="1" colspan="1">9 (64)</td><td align="center" rowspan="1" colspan="1">0.160<sup><xref ref-type="table-fn" rid="TFN3">Q</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Body weight (kg)</td><td align="center" rowspan="1" colspan="1">72.71&#x000b1;12.58 (71.9)</td><td align="center" rowspan="1" colspan="1">72.82&#x000b1;11.21 (71.2)</td><td align="center" rowspan="1" colspan="1">65.95&#x000b1;10.69 (66)</td><td align="center" rowspan="1" colspan="1">73.78&#x000b1;18.66 (69.2)</td><td align="center" rowspan="1" colspan="1">0.513<sup><xref ref-type="table-fn" rid="TFN2">K</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Height (m)</td><td align="center" rowspan="1" colspan="1">1.67&#x000b1;0.10 (1.64)</td><td align="center" rowspan="1" colspan="1">1.63&#x000b1;0.08 (1.62)</td><td align="center" rowspan="1" colspan="1">1.64&#x000b1;0.07 (1.64)</td><td align="center" rowspan="1" colspan="1">1.64&#x000b1;0.10 (1.64)</td><td align="center" rowspan="1" colspan="1">0.663<sup><xref ref-type="table-fn" rid="TFN1">A</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">BMI (kg/m<sup>2</sup>)</td><td align="center" rowspan="1" colspan="1">26.26&#x000b1;3.59 (26.6)</td><td align="center" rowspan="1" colspan="1">26.49&#x000b1;3.38 (26.3)</td><td align="center" rowspan="1" colspan="1">25.27&#x000b1;3.48 (25.4)</td><td align="center" rowspan="1" colspan="1">27.26&#x000b1;5.64 (25.7)</td><td align="center" rowspan="1" colspan="1">0.911<sup><xref ref-type="table-fn" rid="TFN2">K</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Waist circumference (cm)</td><td align="center" rowspan="1" colspan="1">92.32&#x000b1;8.30 (90)</td><td align="center" rowspan="1" colspan="1">97.71&#x000b1;8.55 (97.5)</td><td align="center" rowspan="1" colspan="1">91.50&#x000b1;12.56 (91)</td><td align="center" rowspan="1" colspan="1">97.21&#x000b1;13 (97.5)</td><td align="center" rowspan="1" colspan="1">0.295<sup><xref ref-type="table-fn" rid="TFN1">A</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Hip circumference (cm)</td><td align="center" rowspan="1" colspan="1">95.00&#x000b1;5.72 (96)</td><td align="center" rowspan="1" colspan="1">95.50&#x000b1;6.65 (93)</td><td align="center" rowspan="1" colspan="1">95.03&#x000b1;11.04 (96.5)</td><td align="center" rowspan="1" colspan="1">99.50&#x000b1;11.91 (101)</td><td align="center" rowspan="1" colspan="1">0.625<sup><xref ref-type="table-fn" rid="TFN2">K</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Waist-hip ratio</td><td align="center" rowspan="1" colspan="1">0.95&#x000b1;0.09 (0.9)</td><td align="center" rowspan="1" colspan="1">0.99&#x000b1;0.09 (1)</td><td align="center" rowspan="1" colspan="1">0.97&#x000b1;0.08 (1)</td><td align="center" rowspan="1" colspan="1">1.00&#x000b1;0.09 (1)</td><td align="center" rowspan="1" colspan="1">0.361<sup><xref ref-type="table-fn" rid="TFN1">A</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">SGA A. number (%)</td><td align="center" rowspan="1" colspan="1">11 (79)</td><td align="center" rowspan="1" colspan="1">13 (93)</td><td align="center" rowspan="1" colspan="1">13 (87)</td><td align="center" rowspan="1" colspan="1">13 (93)</td><td align="center" rowspan="1" colspan="1">0.617<sup><xref ref-type="table-fn" rid="TFN3">Q</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="TFN1"><label>A</label><p>ANOVA;</p></fn><fn id="TFN2"><label>K</label><p>Kruskal-Wallis;</p></fn><fn id="TFN3"><label>Q</label><p>Chi-square</p></fn><fn id="TFN4"><p>BMI=body mass index; CHO group = fasting abbreviation with carbohydrate;
CHO+W3 group = fasting abbreviation with carbohydrate and perioperative
infusion of &#x003c9;-3 PUFA; Control group = fasting abbreviation with
water; n=number; <italic>P</italic>=probability; SGA=subjective global
assessment; W3 group = fasting abbreviation with water and perioperative
infusion of &#x003c9;-3 PUFA</p><p>Data expressed as mean &#x000b1; standard deviation; median in parentheses
for continuous variables or number (%) for categorical variables.</p></fn></table-wrap-foot></table-wrap><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><p>Clinical data and risk factors for coronary disease in 57 patients undergoing
on-pump CABG.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">CHO (n=14)</th><th align="center" rowspan="1" colspan="1">Control (n=14)</th><th align="center" rowspan="1" colspan="1">CHO+W3 (n=15)</th><th align="center" rowspan="1" colspan="1">W3 (n=14)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">LVEF</td><td align="center" rowspan="1" colspan="1">0.55&#x000b1;0.12 (0.60)</td><td align="center" rowspan="1" colspan="1">0.57&#x000b1;0.11 (0.60)</td><td align="center" rowspan="1" colspan="1">0.54&#x000b1;0.13 (0.60)</td><td align="center" rowspan="1" colspan="1">0.62&#x000b1;0.11 (0.65)</td><td align="center" rowspan="1" colspan="1">0.168<sup><xref ref-type="table-fn" rid="TFN5">K</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Smoking</td><td align="center" rowspan="1" colspan="1">6 (43)</td><td align="center" rowspan="1" colspan="1">9 (64)</td><td align="center" rowspan="1" colspan="1">7 (47)</td><td align="center" rowspan="1" colspan="1">8 (57)</td><td align="center" rowspan="1" colspan="1">0.653<sup><xref ref-type="table-fn" rid="TFN6">Q</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="center" rowspan="1" colspan="1">4 (29)</td><td align="center" rowspan="1" colspan="1">3 (21)</td><td align="center" rowspan="1" colspan="1">5 (33)</td><td align="center" rowspan="1" colspan="1">6 (43)</td><td align="center" rowspan="1" colspan="1">0.666<sup><xref ref-type="table-fn" rid="TFN6">Q</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Dyslipidemia</td><td align="center" rowspan="1" colspan="1">11 (79)</td><td align="center" rowspan="1" colspan="1">12 (86)</td><td align="center" rowspan="1" colspan="1">8 (53)</td><td align="center" rowspan="1" colspan="1">11 (79)</td><td align="center" rowspan="1" colspan="1">0.204<sup><xref ref-type="table-fn" rid="TFN6">Q</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Previous AMI</td><td align="center" rowspan="1" colspan="1">7 (50)</td><td align="center" rowspan="1" colspan="1">9 (64)</td><td align="center" rowspan="1" colspan="1">6 (40)</td><td align="center" rowspan="1" colspan="1">7 (50)</td><td align="center" rowspan="1" colspan="1">0.631<sup><xref ref-type="table-fn" rid="TFN6">Q</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Use of beta blockers</td><td align="center" rowspan="1" colspan="1">9 (64)</td><td align="center" rowspan="1" colspan="1">10 (71)</td><td align="center" rowspan="1" colspan="1">6 (40)</td><td align="center" rowspan="1" colspan="1">11 (79)</td><td align="center" rowspan="1" colspan="1">0.151<sup><xref ref-type="table-fn" rid="TFN6">Q</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Use of statins</td><td align="center" rowspan="1" colspan="1">11 (79)</td><td align="center" rowspan="1" colspan="1">11 (79)</td><td align="center" rowspan="1" colspan="1">9 (60)</td><td align="center" rowspan="1" colspan="1">11 (79)</td><td align="center" rowspan="1" colspan="1">0.580<sup><xref ref-type="table-fn" rid="TFN6">Q</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Use of fibrates</td><td align="center" rowspan="1" colspan="1">2 (14)</td><td align="center" rowspan="1" colspan="1">2 (14)</td><td align="center" rowspan="1" colspan="1">2 (13)</td><td align="center" rowspan="1" colspan="1">3 (21)</td><td align="center" rowspan="1" colspan="1">0.930<sup><xref ref-type="table-fn" rid="TFN6">Q</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Previous angioplasty</td><td align="center" rowspan="1" colspan="1">1 (7)</td><td align="center" rowspan="1" colspan="1">4 (29)</td><td align="center" rowspan="1" colspan="1">4 (27)</td><td align="center" rowspan="1" colspan="1">3 (21)</td><td align="center" rowspan="1" colspan="1">0.495<sup><xref ref-type="table-fn" rid="TFN6">Q</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="TFN5"><label>K</label><p>Kruskal-Wallis;</p></fn><fn id="TFN6"><label>Q</label><p>Chi-square</p></fn><fn id="TFN7"><p>AMI=acute myocardial infarction; CHO group = fasting abbreviation with
carbohydrate; CHO+W3 group = fasting abbreviation with carbohydrate and
perioperative infusion of &#x003c9;-3 PUFA; Control group = fasting
abbreviation with water; LVEF=left ventricular ejection fraction;
n=number; P=probability; W3 group = fasting abbreviation with water and
perioperative infusion of &#x003c9;-3 PUFA</p><p>Data expressed as mean &#x000b1; standard deviation; median in parentheses
for continuous variables or number (%) for categorical variables.</p></fn></table-wrap-foot></table-wrap><sec><title>Intraoperative Period</title><p>There was no incidence of bronchial aspiration during orotracheal intubation nor
after anesthesia had worn off. No deaths occurred in the operating room.
Intraoperative data are shown in <xref rid="t3" ref-type="table">Table 3</xref>.
There was no statistically significant difference among groups
(<italic>P</italic>&#x0003e;0.05).</p><table-wrap id="t3" orientation="portrait" position="float"><label>Table 3</label><caption><p>Intraoperative clinical data in 57 patients undergoing CABG with CPB.</p></caption><table frame="hsides" rules="all"><colgroup span="1"><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/><col width="16%" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">&#x000a0;</th><th align="center" rowspan="1" colspan="1">CHO (n=14)</th><th align="center" rowspan="1" colspan="1">Control (n=14)</th><th align="center" rowspan="1" colspan="1">CHO+W3 (n=15)</th><th align="center" rowspan="1" colspan="1">W3 (n=14)</th><th align="center" rowspan="1" colspan="1"><italic>P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Total duration of surgery (min)</td><td align="center" rowspan="1" colspan="1">244.64&#x000b1;40.31 (240)</td><td align="center" rowspan="1" colspan="1">232.31&#x000b1;49.27 (225)</td><td align="center" rowspan="1" colspan="1">249.29&#x000b1;24.01 (240)</td><td align="center" rowspan="1" colspan="1">253.93&#x000b1;40.86 (270)</td><td align="center" rowspan="1" colspan="1">0.532<sup><xref ref-type="table-fn" rid="TFN8">A</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">CPB time (min)</td><td align="center" rowspan="1" colspan="1">77.14&#x000b1;20.37 (82.5)</td><td align="center" rowspan="1" colspan="1">66.64&#x000b1;24.50 (60)</td><td align="center" rowspan="1" colspan="1">63.53&#x000b1;15.63 (66)</td><td align="center" rowspan="1" colspan="1">78.79&#x000b1;22.93 (85)</td><td align="center" rowspan="1" colspan="1">0.147<sup><xref ref-type="table-fn" rid="TFN8">A</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">CC time (min)</td><td align="center" rowspan="1" colspan="1">63.71&#x000b1;17.29 (66.5)</td><td align="center" rowspan="1" colspan="1">56.86&#x000b1;28.21 (50.5)</td><td align="center" rowspan="1" colspan="1">54.20&#x000b1;15.52 (56)</td><td align="center" rowspan="1" colspan="1">61.57&#x000b1;18.58 (68)</td><td align="center" rowspan="1" colspan="1">0.586<sup><xref ref-type="table-fn" rid="TFN8">A</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Need for transfusion</td><td align="center" rowspan="1" colspan="1">7 (50)</td><td align="center" rowspan="1" colspan="1">7 (50)</td><td align="center" rowspan="1" colspan="1">7 (47)</td><td align="center" rowspan="1" colspan="1">8 (57)</td><td align="center" rowspan="1" colspan="1">0.953<sup><xref ref-type="table-fn" rid="TFN9">Q</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Number of grafts</td><td align="center" rowspan="1" colspan="1">3.00&#x000b1;0.96 (3)</td><td align="center" rowspan="1" colspan="1">2.36&#x000b1;0.93 (2)</td><td align="center" rowspan="1" colspan="1">2.67&#x000b1;0.82 (3)</td><td align="center" rowspan="1" colspan="1">2.86&#x000b1;0.86 (3)</td><td align="center" rowspan="1" colspan="1">0.266<sup><xref ref-type="table-fn" rid="TFN8">A</xref></sup></td></tr><tr><td align="left" rowspan="1" colspan="1">Complications</td><td align="center" rowspan="1" colspan="1">1 (7)</td><td align="center" rowspan="1" colspan="1">2 (14)</td><td align="center" rowspan="1" colspan="1">0 (0)</td><td align="center" rowspan="1" colspan="1">1 (7)</td><td align="center" rowspan="1" colspan="1">0.519<sup><xref ref-type="table-fn" rid="TFN9">Q</xref></sup></td></tr></tbody></table><table-wrap-foot><fn id="TFN8"><label>A</label><p>ANOVA;</p></fn><fn id="TFN9"><label>Q</label><p>Chi-Square</p></fn><fn id="TFN10"><p>CC=cross-clamp; CPB=cardiopulmonary bypass; CHO group=fasting
abbreviation with carbohydrate; CHO+W3 group=fasting abbreviation
with carbohydrate and perioperative infusion of &#x003c9;-3 PUFA;
Control group=fasting abbreviation with water; n=number;
P=probability; W3 group=fasting abbreviation with water and
perioperative infusion of &#x003c9;-3 PUFA</p><p>Data expressed as mean &#x000b1; standard deviation; median in
parentheses for continuous variables or number (%) for categorical
variables.</p></fn></table-wrap-foot></table-wrap><p>Although the number of patients who needed vasoactive drugs (dobutamine and/or
norepinephrine) for weaning from CPB was higher in the Control group, no
significant difference per group was found (CHO: 7/14, 50.0%; Control: 12/14,
85.7%; CHO+W3: 6/15, 40.0%; W3: 9/14, 64.3%; <italic>P</italic>=0.071) (<xref ref-type="fig" rid="f3">Figure 3</xref>). Patients in groups with fasting
abbreviation and CHO intake (CHO and CHO+W3 groups) needed fewer vasoactive
drugs compared to the other groups (RR=0.60; 95% CI: 0.38-0.94;
<italic>P</italic>=0.020) (<italic>P</italic>=0.035).</p><p>
<fig id="f3" orientation="portrait" position="float"><label>Fig. 3</label><caption><p>Group distributions of vasoactive drugs required for weaning from
CPB.</p></caption><graphic xlink:href="rbccv-34-02-0125-g03"/></fig>
</p></sec><sec><title>Postoperative Period</title><p>Overall mean ICU length of stay was 3.11&#x000b1;1.88 days (2-14), with no
significant difference shown in means &#x000b1; standard deviations per group
(<italic>P</italic>=0.713), as follows: CHO group, 2.86&#x000b1;1.23 days
(median: 2); Control group, 3.43&#x000b1;3.16 days (median: 2); CHO+W3 group,
2.80&#x000b1;0.94 days (median: 3); and W3 group, 3.36&#x000b1;1.55 days (median:
3). Likewise, there was no significant difference in total postoperative length
of hospital stay among groups, with an overall mean of 7.75&#x000b1;3.62 days
observed (<italic>P</italic>=0.980).</p><p>The number of patients requiring vasoactive drugs (dobutamine and/or
norepinephrine) during recovery in the ICU differed significantly among the
groups (CHO, 3/14; 21.4%; Control, 10/14; 71.4%; CHO+W3, 3/15; 20.0%; W3, 8/14;
57.1%; <italic>P</italic>=0.008). Patients receiving CHO (CHO and CHO+W3 groups)
had substantially lower needs for these drugs compared to the other groups
(<xref ref-type="fig" rid="f4">Figure 4</xref>).</p><p>
<fig id="f4" orientation="portrait" position="float"><label>Fig. 4</label><caption><p>Group distributions of vasoactive drugs required during ICU
recovery.</p></caption><graphic xlink:href="rbccv-34-02-0125-g04"/></fig>
</p><p>Incidence of POAF per group differed statistically (<italic>P</italic>=0.009),
with overall incidence of 29.8% (17 patients). Six patients (42.9%) presented
POAF in the CHO group, eight (57.1%) in the Control group, one (6.7%) in the
CHO+W3 group, and two (14.3%) in the W3 group. A significantly lower incidence
of POAF was observed in patients who received &#x003c9;-3 PUFA (CHO+W3 and W3
groups) (<italic>P</italic>=0.001): only three patients (10.3%) receiving
&#x003c9;-3 PUFA developed POAF, the other 14 (50.0%) belonging to the other two
groups. Thus, 50.0% of the patients who did not receive &#x003c9;-3 PUFA
developed POAF, a percentage 4.83 times higher than the groups that received it
(RR=4.83; 95% CI: 1.56-15.02).</p><p>The amount of bleeding in the first 12 hours of recovery in the ICU was
266.92&#x000b1;214.51 mL, with a median of 200&#x000b1;86 mL. There was no
statistically significant difference among groups (<italic>P</italic>=0.351).
The use of packed red blood cells or blood components did not differ among
groups in the operating room and in the ICU (<italic>P</italic>&#x0003e;0.05).</p></sec><sec><title>Infectious Complications</title><p>The overall incidence of infectious complications in the ICU was 7.0% (4
patients). All four patients were diagnosed with postoperative pneumonia, two
patients from the W3 group and one patient each from the CHO and Control groups,
without statistical difference among groups (<italic>P</italic>=0.519). There
were no cases of either surgical wound infections or mediastinitis in the ICU.
No statistical difference was observed in the number of patients diagnosed with
any type of infection during recovery in the hospital ward
(<italic>P</italic>=0.179). There was a superficial infection of the
saphenectomy wound in two patients from the W3 group and in another two from the
Control group, and one of the last patients also had an infection in the lower
third of the thoracic surgical wound (median incision). One patient from the W3
group, two from the CHO group, and another two from the Control group had
pneumonia during the hospital ward recovery.</p><p>None of the patients developed sepsis or mediastinitis in the ward. Considering
the incidence of infectious complications per group during the entire
postoperative period, no statistically significant difference between groups was
found (<italic>P</italic>=0.069), even though the <italic>P</italic> value was
close to statistical significance due to the lower cases of complications found
in patients of the groups receiving CHO (CHO and CHO+W3 groups) (RR=0.29; 95%
CI: 0.09-0.94; <italic>P</italic>=0.023).</p></sec><sec><title>Incidence of Combined Major Cardiovascular Events</title><p>Postoperative CVA occurred in 5.3% of the patients (3 patients). Two of the
patients were in the ICU: one, from the Control group, had early CVA and died;
the other, from the CHO+W3 group, had late CVA and developed left-sided
hemiplegia, with partial recovery at hospital discharge. The third patient, also
from the Control group, was diagnosed with transient ischemic attack in the
hospital ward and was discharged without sequelae. Two patients (3.5%) presented
postoperative AMI during recovery in the ICU, one from the CHO and the other
from the W3 group. The patient from the W3 group died and there were no
repercussions from this event in the patient from the Control group.</p><p>Therefore, as mentioned above, two deaths (3.5%) of patients from the Control and
W3 groups were recorded, both in ICU recovery and with no statistical difference
between the groups (<italic>P</italic>=0.543). In addition, two patients
developed postoperative AMI and three patients suffered a CVA. The incidence of
combined events (CVA, AMI, and Mortality) was not statistically significant
(<italic>P</italic>&#x0003e;0.05).</p></sec><sec><title>Blood Glucose Levels and Insulin Resistance</title><p>There were no statistically significant differences between groups for the three
capillary blood glucose serial tests performed intraoperatively
(<italic>P</italic>=0.425). However, when analyzing the isolated and
progressive behavior of these tests in groups of patients who were did not
receive CHO (<italic>i.e</italic>., Control and W3 groups), a significant
increase was observed in the means of the second and third tests compared to
values at the beginning of surgery (<italic>P</italic>=0.022). Of the total
number of patients assessed, 77.2% (44) required intraoperative exogenous
insulin, in equal amounts and equally distributed across the groups
<italic>(P</italic>&#x0003e;0.05).</p><p>Likewise, there was no significant difference between the groups for the
capillary blood glucose serial tests performed in the first six hours of
recovery in the ICU (<italic>P</italic>=0.079) (<xref ref-type="fig" rid="f5">Figure 5</xref>). Nevertheless, it was observed that both groups with
patients receiving CHO (CHO and CHO+W3) tended to have better glycemic control.
Based on this pattern, results of these two groups (CHO and CHO+W3) were
combined and compared with each other (Control and W3). With this new clustering
of data, a statistically significant difference was found between the two new
clusters (<italic>P</italic>=0.015), showing better glycemic control in groups
with brief fasting and CHO intake (<xref ref-type="fig" rid="f6">Figure
6</xref>).</p><p>
<fig id="f5" orientation="portrait" position="float"><label>Fig. 5</label><caption><p>Average capillary blood glucose levels during the first 6
postoperative hours in the ICU, according to groups. Note: the
dotted line indicates the 150 mg/dL limit and the regular use of
exogenous insulin.</p></caption><graphic xlink:href="rbccv-34-02-0125-g05"/></fig>
</p><p>
<fig id="f6" orientation="portrait" position="float"><label>Fig. 6</label><caption><p>Average capillary blood glucose levels during the first 6
postoperative hours in the ICU, according to a new grouping: fasting
abbreviation with CHO (CHO and CHO+W3) vs. groups receiving
abbreviation with water (Control and W3). Note: the dotted line
indicates the 150 mg/dL limit and the regular use of exogenous
insulin.</p></caption><graphic xlink:href="rbccv-34-02-0125-g06"/></fig>
</p><p>Only four patients (7.0%) did not need exogenous insulin in the ICU to control
glycemia. Overall mean for insulin use in the ICU was 22.67&#x000b1;13.36 IU in
six hours. On average, the CHO group needed 16&#x000b1;14.38 IU; the Control
group, 25.43&#x000b1;11.62 IU; the CHO+W3 group, 19.0&#x000b1;9.59 IU; and the W3
group, 30.29&#x000b1;14.01 IU. The difference between groups was statistically
significant (<italic>P</italic>=0.018) due to the low use of insulin for
glycemic control in patients who received CHO.</p></sec><sec><title>Inflammatory Response - Inflammatory Markers</title><p>Regardless of which group they belonged to, all patients presented a significant
increase in ultrasensitive CRP in the serial tests conducted over time
(<italic>P</italic>&#x0003c;0.001). This increase occurred mainly after the
4<sup>th</sup> test, which corresponds to the postoperative period or
arrival at the ICU. No statistical difference between groups was found
(<italic>P</italic>=0.621); however, in the 7<sup>th</sup> test (36h PO),
mean CRP levels were significantly lower in the W3 group (mean: 4.46&#x000b1;3.37
mg/dL) than in the other groups (mean: 7.24&#x000b1;7.40 mg/dL)
(<italic>P</italic>=0.008) (<xref ref-type="fig" rid="f7">Figure
7</xref>).</p><p>
<fig id="f7" orientation="portrait" position="float"><label>Fig. 7</label><caption><p>Average level of the CRP inflammatory marker per group, taken from
seven serial blood tests. *Refers to case-by-case analysis between
groups at 36 hours postoperatively (P=0.008). Note: the dotted line
indicates the reference value for acute inflammation used by the
laboratory.</p></caption><graphic xlink:href="rbccv-34-02-0125-g07"/></fig>
</p><p>Regarding interleukins, there was no statistical difference between the groups
for IL-6 (<italic>P</italic>=0.105), due to the large range of variation and
standard deviation found. On the other hand, the results for IL-10 showed a
significant association between groups and serial tests
(<italic>P</italic>=0.013) (<xref ref-type="fig" rid="f8">Figure 8</xref>). In
addition, it was observed that groups of patients who received &#x003c9;-3 PUFA
(CHO+W3 and W3 groups) showed a significantly lower drop
(<italic>P</italic>=0.049) in mean values of postoperative recovery period (ICU,
6h, 12h, and 36h), when compared to the groups that did not receive it.</p><p>
<fig id="f8" orientation="portrait" position="float"><label>Fig. 8</label><caption><p>Average level of the IL-10 inflammatory marker per group, taken from
seven serial blood tests.</p></caption><graphic xlink:href="rbccv-34-02-0125-g08"/></fig>
</p></sec></sec><sec sec-type="discussion"><title>DISCUSSION</title><p>Overall, results show that abbreviation of preoperative fasting with CHO intake
associated with intravenous &#x003c9;-3 PUFA is safe and adequate for patients
undergoing on-pump CABG. Not only because patients needed less vasoactive drugs
during weaning from CPB or ICU recovery, but also due to lower incidence of POAF,
improved metabolic control, and reduced postoperative inflammatory response.</p><p>Multimodal protocols are used globally in cardiovascular surgery, and indeed are a
recommended practice in CABG guidelines<sup>[<xref rid="r5" ref-type="bibr">5</xref>,<xref rid="r18" ref-type="bibr">18</xref>,<xref rid="r19" ref-type="bibr">19</xref>]</sup>. De Vries et al.<sup>[<xref rid="r1" ref-type="bibr">1</xref>]</sup> compared 3,760 patients who underwent CABG before
the implementation of a checklist protocol for 3,820 patients undergoing the
procedure after implementation. The number of complications per 100 patients was
reduced from 27.3 (95% CI: 25.9-28.7) to 16.7 (95% CI: 15.6-17.9) and the percentage
of patients with one or more complications dropped from 15.4% to 10.6%
(<italic>P</italic>&#x0003c;0.001). Moreover, there was a reduction in hospital
mortality. In Brazil, several centers are concerned with creating, implementing and
adapting multimodal protocols - <italic>i.e</italic>., establishing a Heart Team -
in addition to maintaining databases in order to evaluate results and adopt measures
for general improvement in the services provided<sup>[<xref rid="r20" ref-type="bibr">20</xref>,<xref rid="r21" ref-type="bibr">21</xref>]</sup>.</p><p>Similarly to studies related to the ACERTO Project, the results of this study did not
show cases of bronchial aspiration in groups that received CHO and in those who
received only water<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>,<xref rid="r6" ref-type="bibr">6</xref>,<xref rid="r14" ref-type="bibr">14</xref>]</sup>. Furthermore,
published studies have stated the safety of using &#x003c9;-3 PUFA in a range of
surgical fields in spite of possible effects of oil on platelet function<sup>[<xref rid="r22" ref-type="bibr">22</xref>]</sup>.</p><p>The outcomes of this protocol are comparable with two previous studies that showed
faster postoperative recovery and less need for vasoactive drugs in patients who
underwent fasting abbreviation with CHO intake before cardiovascular
surgery<sup>[<xref rid="r15" ref-type="bibr">15</xref>,<xref rid="r16" ref-type="bibr">16</xref>]</sup>. In fact, abbreviation of fasting and CHO intake
is nothing new; several centers have stopped practicing prolonged fasting, including
for patients undergoing cardiovascular surgery<sup>[<xref rid="r17" ref-type="bibr">17</xref>,<xref rid="r23" ref-type="bibr">23</xref>]</sup>. Brief fasting
reduces insulin resistance, improves metabolic control, and relieves hunger and
thirst in the postoperative period<sup>[<xref rid="r2" ref-type="bibr">2</xref>,<xref rid="r3" ref-type="bibr">3</xref>]</sup>. In cardiovascular
surgery, there are still few studies that corroborate these findings; therefore, the
results of this study are particularly relevant.</p><p>Glycemic and metabolic control is a unique aspect in cardiovascular surgery as it is
closely linked to possible clinical outcomes and morbidity and mortality during
hospitalization<sup>[<xref rid="r24" ref-type="bibr">24</xref>]</sup>.
Furnary et al.<sup>[<xref rid="r25" ref-type="bibr">25</xref>]</sup> analyzed 4,864
patients undergoing cardiovascular surgery, in which perioperative hyperglycemia was
associated with higher rates of mediastinitis, prolonged hospital stay, and
increased costs. In a recent study, Jarvela et al.<sup>[<xref rid="r26" ref-type="bibr">26</xref>]</sup> assessed 1,356 patients undergoing cardiovascular
surgery with tight control of repetitive glucose spikes (which can occur in the
perioperative period). The authors stated that it occurred in 39.7% of the patients
and was associated with higher rates of infection, 12.1% <italic>vs</italic>. 8.2%
(<italic>P</italic>=0.019), CVA, 4.9% <italic>vs</italic>. 1.5%
(<italic>P</italic>&#x0003c;0.001), and mortality, 6.1% <italic>vs</italic>. 2.1%
(<italic>P</italic>&#x0003c;0.001), when compared with patients with blood glucose
levels within the normal range or slightly higher.</p><p>Much has been discussed about glycemic control and insulin therapy in cardiovascular
surgery. Researchers have sought target values - <italic>e.g</italic>., 180 mg/dL,
less than 150 mg/dL, or even tighter at 110 mg/dL - to better control metabolism and
insulin resistance<sup>[<xref rid="r27" ref-type="bibr">27</xref>,<xref rid="r28" ref-type="bibr">28</xref>]</sup>. In a recent meta-analysis of 36
randomized studies involving 17,996 patients, Yamada et al.<sup>[<xref rid="r29" ref-type="bibr">29</xref>]</sup>assessed four different types of
insulin therapy regimen (very mild, mild, moderate, and tight) to treat
hyperglycemia in critically ill patients. Their findings indicate that tighter
control does not lower the risk of short-term mortality when compared to the very
mild regimen [tight (RR=0.94; 95% CI 0.83-1.07; <italic>P</italic>=0.36); moderate
(RR=1.1; 95% CI: 0.66-1.84; <italic>P</italic>=0.72); and mild (RR=0.88; 95% CI:
0.73-1.06; <italic>P</italic>=0.18)]. In addition, tight control led to a higher
occurrence of hypoglycemia. In a multicenter study, Sz&#x000e9;kely et al.<sup>[<xref rid="r30" ref-type="bibr">30</xref>]</sup> studied the relationship between
perioperative hyperglycemia and hospital mortality in 5,050 patients undergoing CABG
in 70 cardiovascular surgery centers. Even though mortality was higher among
diabetics (4.2% <italic>vs</italic>. 2.95%; <italic>P</italic>=0.02), hyperglycemia
was not associated with a higher risk of hospital mortality in these patients.
However, in non-diabetic patients, repetitive postoperative glucose spikes between
250-300 mg/dL (RR=2.56; 95% CI: 1.18-5.57; <italic>P</italic>=0.02) and aggressive
use of exogenous insulin postoperatively (RR=2.04; 95% CI: 1.12-3.70;
<italic>P</italic>=0.01) were considered independent risk factors for
mortality.</p><p>The results of this study show that abbreviation of fasting with CHO intake
interfered in the glycemic control, mainly in the ICU. In the Control and W3 groups,
mean capillary blood glucose levels were higher than the pre-established limit of
150 mg/dL starting from the first measurements in the ICU
(<italic>P</italic>&#x0003c;0.05), which indicates that closer attention and insulin
therapy intervention are needed in these groups to achieve better metabolic control.
To test this association, CHO and CHO+W3 groups were clustered and compared to the
other two groups (Control and W3). This new grouping showed a statistically
significant difference between the groups (<italic>P</italic>=0.015) (<xref ref-type="fig" rid="f6">Figure 6</xref>). Furthermore, the mean overall use of
insulin in the ICU was significantly lower in groups that received CHO in comparison
with the other<italic>s (P</italic>=0.018).</p><p>In this study, insulin resistance was assessed through the need for exogenous insulin
as well as oscillations in blood glucose levels postoperatively. This condition may
be aggravated by CPB<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup>. Blood
glucose levels tend to increase during hypothermic CPB, whereas insulin levels tend
to decline. On the other hand, insulin levels fluctuate and may increase
substantially during rewarming, in preparation for weaning from CPB; catecholamines,
cytokines, cortisol, and GH levels also increase<sup>[<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r16" ref-type="bibr">16</xref>]</sup>.</p><p>Inflammation is another relevant issue in cardiovascular surgery. On-pump CABG may
trigger the development of SIRS and activation of the complement system, which
worsens insulin resistance<sup>[<xref rid="r31" ref-type="bibr">31</xref>]</sup>.
The patient's blood in contact with non-biocompatible surfaces of the CPB circuit,
surgical trauma, and reperfusion injury caused by the method have been considered
precise mechanisms for this event. Restoring blood flow at the end of CPB
(reperfusion) may worsen lesions caused by ischemia, leading to irreversible injury,
release of inflammatory mediators, and apoptosis. Reintroduction of molecular oxygen
in ischemic tissue produces oxygen-free radicals, which are harmful to cells and may
induce acute systemic inflammatory response<sup>[<xref rid="r8" ref-type="bibr">8</xref>]</sup>.</p><p>Regular perioperative use of agents such as corticosteroids and mannitol, among
others, has been evaluated and some studies have shown its benefits towards
minimizing SIRS after CPB<sup>[<xref rid="r7" ref-type="bibr">7</xref>,<xref rid="r32" ref-type="bibr">32</xref>]</sup>. Although this remains a
controversial topic and not yet completely defined in the literature, patients in
this study received corticosteroids during induction of anesthesia and mannitol
during CPB. Indeed, in a recent publication (European guideline), its routine use in
patients undergoing cardiovascular surgery is no longer recommended<sup>[<xref rid="r33" ref-type="bibr">33</xref>]</sup>.</p><p>A reasonable alternative, currently under discussion for cardiovascular surgery, is
the use of pre- or perioperative &#x003c9;-3 PUFA. Berger et al.<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>carried out a randomized
placebo-controlled study to assess some inflammatory markers in two groups: the
first group received &#x003c9;-3 PUFA (0.2 g/kg) infusions 12 and 2 hours
preoperatively and immediately after surgery; the other received saline solution as
placebo (control). There was a significant decrease in postoperative IL-6
(<italic>P</italic>=0.018) and IL-8 (<italic>P</italic>=0.005) in the &#x003c9;-3
PUFA group, in addition to a reduction in the incidence of arrhythmia, though the
latter was not statistically significant. Additionally, plasma concentrations of
glucose, lactate, and carboxyhemoglobin were also lower in the intervention group
compared to the control group (<italic>P</italic>&#x0003c;0.05).</p><p>The benefits of &#x003c9;-3 PUFA have been reported for decades in several medical
specialties, particularly in cardiology and intensive care. Intravenous &#x003c9;-3
PUFA is rapidly incorporated by cell membranes<sup>[<xref rid="r10" ref-type="bibr">10</xref>]</sup> and may minimize the production of pro-inflammatory
mediators<sup>[<xref rid="r11" ref-type="bibr">11</xref>]</sup>. These
anti-inflammatory properties may lead to shorter hospitalizations and fewer severe
infections in critically ill patients. They have also been associated with a lower
incidence of postoperative complications and possibly lower mortality from acute
lung injury<sup>[<xref rid="r34" ref-type="bibr">34</xref>]</sup>. In cardiology,
benefits include less morbidity and mortality from congestive heart failure and
lower mortality rate from sudden death after AMI<sup>[<xref rid="r35" ref-type="bibr">35</xref>]</sup>. Use of &#x003c9;-3 PUFA has also been linked to
better control of dyslipidemia, heart rate, and chronic atrial
fibrillation<sup>[<xref rid="r36" ref-type="bibr">36</xref>]</sup>.
Nonetheless, the literature is conflicting since some studies have not confirmed
those benefits<sup>[<xref rid="r37" ref-type="bibr">37</xref>]</sup>.</p><p>The protocol in this study has shown lower incidence of POAF, in accordance with
recent findings from a meta-analysis by Langlois et al.<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>. The authors described a systematic review of 19
randomized clinical trials with 4,335 patients who underwent cardiovascular surgery.
Similarly to what was observed in our study, the meta-analysis could not identify
the effect of &#x003c9;-3 PUFA on ICU length of stay and postoperative mortality.
However, infusion of &#x003c9;-3 PUFA was associated with shorter hospital stay and
lower POAF rate, especially with CPB. Reduced POAF observed in our patients and in
the meta-analysis described above may likely be related to the lower postoperative
inflammatory response as a result of the infusion of &#x003c9;-3 PUFA, although we
know that POAF mechanisms have multiple factors and are different from those found
in paroxysmal atrial fibrillation<sup>[<xref rid="r12" ref-type="bibr">12</xref>]</sup>.</p><p>This study has also shown interesting findings related to postoperative inflammatory
response and &#x003c9;-3 PUFA. IL-10, the only cytokine with measured
anti-inflammatory properties, was statistically different per group
(<italic>P</italic>=0.013) and remained higher postoperatively in patients who
received &#x003c9;-3 PUFA (<italic>P</italic>=0.049). Likewise, patients from the W3
group, who received only &#x003c9;-3 PUFA, had lower levels of ultrasensitive
C-reactive protein (PCR) within 36 hours postoperatively
(<italic>P</italic>=0.008).</p><p>The findings presented in this study must be interpreted with caution since the
sample size was a limiting factor. Additional studies about the issues presented
here are warranted given the promising effects of both interventions on metabolism
and postoperative inflammation.</p></sec><sec sec-type="conclusions"><title>CONCLUSION</title><p>From the results observed, it is possible to conclude that the abbreviation of
fasting with CHO associated with perioperative infusion of &#x003c9;-3 PUFA is safe
and supports faster postoperative recovery in patients undergoing on-pump CABG.</p><table-wrap id="t5" orientation="portrait" position="anchor"><table frame="hsides" rules="groups"><colgroup span="1"><col width="5%" span="1"/><col width="95%" span="1"/></colgroup><thead><tr><th align="left" colspan="2" rowspan="1">Authors' roles &#x00026; responsibilities</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">GRF</td><td align="left" valign="top" rowspan="1" colspan="1">Conception and design of the work;
analysis and interpretation of data for the work. Drafting the
manuscript and revising it critically for important intellectual
content; final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">PRLL</td><td align="left" valign="top" rowspan="1" colspan="1">Acquisition of data; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">ACF</td><td align="left" valign="top" rowspan="1" colspan="1">Acquisition of data; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FRHLC</td><td align="left" valign="top" rowspan="1" colspan="1">Acquisition of data; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">DCB</td><td align="left" valign="top" rowspan="1" colspan="1">Acquisition of data; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">LRT</td><td align="left" valign="top" rowspan="1" colspan="1">Acquisition of data; randomization of the
study; final approval of the version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">NJS</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the manuscript and revising it
critically for important intellectual content; final approval of the
version to be published</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">JEAN</td><td align="left" valign="top" rowspan="1" colspan="1">Drafting the manuscript and revising it
critically for important intellectual content; final approval of the
version to be published</td></tr></tbody></table></table-wrap></sec></body><back><fn-group><fn fn-type="other"><p>This study was carried out at Hospital Geral Universit&#x000e1;rio of Universidade
de Cuiab&#x000e1; (HGU-UNIC), Cuiab&#x000e1;, MT, Brazil.</p></fn><fn fn-type="financial-disclosure"><p><bold>Financial Support</bold></p><p>We received partial financial support from CNPq (Conselho Nacional de
Desenvolvimento Cient&#x000ed;fico e Tecnol&#x000f3;gico - "National Council for
Scientific and Technological Development" of Brazil). CNPq Processes
472881/2011-6 e 301631/2015-8.</p></fn><fn fn-type="COI-statement"><p>No conflict of interest.</p></fn></fn-group><ack><title>ACKNOWLEDGEMENTS</title><p>We thank the professionals of the Nutrition team of the General University Hospital
for their commitment to the development of this protocol. We also thank the
professionals of the Anesthesiology and Intensive Care services, who played a
fundamental role in this study.</p></ack><ref-list><title>REFERENCES</title><ref id="r1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Vries</surname><given-names>EN</given-names></name><name><surname>Prins</surname><given-names>HA</given-names></name><name><surname>Crolla</surname><given-names>RM</given-names></name><name><surname>den Outer</surname><given-names>AJ</given-names></name><name><surname>van Andel</surname><given-names>G</given-names></name><name><surname>van Helden</surname><given-names>SH</given-names></name><name><surname>Schlack</surname><given-names>WS</given-names></name><name><surname>van Putten</surname><given-names>MA</given-names></name><name><surname>Gouma</surname><given-names>DJ</given-names></name><name><surname>Dijkgraaf</surname><given-names>MG</given-names></name><name><surname>Smorenburg</surname><given-names>SM</given-names></name><name><surname>Boermeester</surname><given-names>MA</given-names></name><collab>SURPASS Collaborative Group</collab></person-group><article-title>Effect of a comprehensive surgical safety system on patient
outcomes</article-title><source>N Engl J Med</source><day>11</day><month>11</month><year>2010</year><volume>363</volume><issue>20</issue><fpage>1928</fpage><lpage>1937</lpage><pub-id pub-id-type="doi">10.1056/NEJMsa0911535</pub-id><pub-id pub-id-type="pmid">21067384</pub-id></element-citation></ref><ref id="r2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aguilar-Nascimento</surname><given-names>JEd</given-names></name><name><surname>Al</surname><given-names>Bicudo-Salom&#x000e3;o</given-names></name><name><surname>Caporossi</surname><given-names>C</given-names></name><name><surname>Silva</surname><given-names>RM</given-names></name><name><surname>Cardoso</surname><given-names>EA</given-names></name><name><surname>Santos</surname><given-names>TP</given-names></name></person-group><article-title>Enhancing surgical recovery in Central-West Brazil: the ACERTO
protocol results. e-SPEN</article-title><source>Eur J Clin Nutr Metab</source><year>2008</year><volume>3</volume><issue>2</issue><fpage>e78</fpage><lpage>e83</lpage></element-citation></ref><ref id="r3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pimenta</surname><given-names>GP</given-names></name><name><surname>de Aguilar-Nascimento</surname><given-names>JE</given-names></name></person-group><article-title>Prolonged preoperative fasting in elective surgical patients: why
should we reduce it?</article-title><source>Nutr Clin Pract</source><month>2</month><year>2014</year><volume>29</volume><issue>1</issue><fpage>22</fpage><lpage>28</lpage><pub-id pub-id-type="doi">10.1177/0884533613514277</pub-id><pub-id pub-id-type="pmid">24336400</pub-id></element-citation></ref><ref id="r4"><label>4</label><element-citation publication-type="book"><person-group person-group-type="author"><collab>WHO</collab></person-group><source>Cardiovascular disease</source><year>2009</year><publisher-loc>Geneva</publisher-loc><publisher-name>Word Health Organization</publisher-name><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/cardiovascular_diseases/en/">http://www.who.int/cardiovascular_diseases/en/</ext-link></comment></element-citation></ref><ref id="r5"><label>5</label><element-citation publication-type="journal"><comment>Authors/Task Force members</comment><person-group person-group-type="author"><name><surname>Windecker</surname><given-names>S</given-names></name><name><surname>Kolh</surname><given-names>P</given-names></name><name><surname>Alfonso</surname><given-names>F</given-names></name><name><surname>Collet</surname><given-names>JP</given-names></name><name><surname>Cremer</surname><given-names>J</given-names></name><name><surname>Falk</surname><given-names>V</given-names></name><name><surname>Filippatos</surname><given-names>G</given-names></name><name><surname>Hamm</surname><given-names>C</given-names></name><name><surname>Head</surname><given-names>SJ</given-names></name><name><surname>J&#x000fc;ni</surname><given-names>P</given-names></name><name><surname>Kappetein</surname><given-names>AP</given-names></name><name><surname>Kastrati</surname><given-names>A</given-names></name><name><surname>Knuuti</surname><given-names>J</given-names></name><name><surname>Landmesser</surname><given-names>U</given-names></name><name><surname>Laufer</surname><given-names>G</given-names></name><name><surname>Neumann</surname><given-names>FJ</given-names></name><name><surname>Richter</surname><given-names>DJ</given-names></name><name><surname>Schauerte</surname><given-names>P</given-names></name><name><surname>Sousa Uva</surname><given-names>M</given-names></name><name><surname>Stefanini</surname><given-names>GG</given-names></name><name><surname>Taggart</surname><given-names>DP</given-names></name><name><surname>Torracca</surname><given-names>L</given-names></name><name><surname>Valgimigli</surname><given-names>M</given-names></name><name><surname>Wijns</surname><given-names>W</given-names></name><name><surname>Witkowski</surname><given-names>A</given-names></name></person-group><article-title>2014 ESC/EACTS Guidelines on myocardial revascularization: The
Task Force on Myocardial Revascularization of the European Society of
Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery
(EACTS)Developed with the special contribution of the European Association
of Percutaneous Cardiovascular Interventions (EAPCI)</article-title><source>Eur Heart J</source><day>01</day><month>10</month><year>2014</year><volume>35</volume><issue>37</issue><fpage>2541</fpage><lpage>2619</lpage><pub-id pub-id-type="doi">10.1093/eurheartj/ehu278</pub-id><pub-id pub-id-type="pmid">25173339</pub-id></element-citation></ref><ref id="r6"><label>6</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Feguri</surname><given-names>GR</given-names></name><name><surname>Braile</surname><given-names>DM</given-names></name><name><surname>Aguilar-Nascimento</surname><given-names>JE</given-names></name></person-group><chapter-title>Projeto ACERTO em cirurgia cardiovascular</chapter-title><person-group person-group-type="editor"><name><surname>Aguilar-Nascimento</surname><given-names>JE</given-names></name><name><surname>Caporossi</surname><given-names>C</given-names></name><name><surname>Salom&#x000e3;o</surname><given-names>AB</given-names></name></person-group><source>ACERTO: Acelerando a Recupera&#x000e7;&#x000e3;o Total
P&#x000f3;s-Operat&#x000f3;ria</source><year>2016</year><edition>3a ed</edition><publisher-loc>Rio de Janeiro</publisher-loc><publisher-name>Rubio</publisher-name><fpage>283</fpage><lpage>300</lpage></element-citation></ref><ref id="r7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brasil</surname><given-names>LA</given-names></name><name><surname>Gomes</surname><given-names>WJ</given-names></name><name><surname>Salom&#x000e3;o</surname><given-names>R</given-names></name><name><surname>Fonseca</surname><given-names>JH</given-names></name><name><surname>Branco</surname><given-names>JN</given-names></name><name><surname>Buffolo</surname><given-names>E</given-names></name></person-group><article-title>Uso de cortic&#x000f3;ide como inibidor da resposta
inflamat&#x000f3;ria sist&#x000ea;mica induzida pela circula&#x000e7;&#x000e3;o
extracorp&#x000f3;rea</article-title><source>Rev Bras Cir Cardiovasc</source><comment>[Internet]</comment><year>1999</year><date-in-citation content-type="access-date">2019 Feb 09</date-in-citation><volume>14</volume><issue>3</issue><fpage>254</fpage><lpage>268</lpage><comment>Available from: </comment><pub-id pub-id-type="doi">10.1590/S0102-76381999000300010</pub-id></element-citation></ref><ref id="r8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Landis</surname><given-names>RC</given-names></name><name><surname>Brown</surname><given-names>JR</given-names></name><name><surname>Fitzgerald</surname><given-names>D</given-names></name><name><surname>Likosky</surname><given-names>DS</given-names></name><name><surname>Shore-Lesserson</surname><given-names>L</given-names></name><name><surname>Baker</surname><given-names>RA</given-names></name><name><surname>Hammon</surname><given-names>JW</given-names></name></person-group><article-title>Attenuating the Systemic Inflammatory Response to Adult
Cardiopulmonary Bypass: A Critical Review of the Evidence
Base</article-title><source>J Extra Corpor Technol</source><month>9</month><year>2014</year><volume>46</volume><issue>3</issue><fpage>197</fpage><lpage>211</lpage><pub-id pub-id-type="pmid">26357785</pub-id></element-citation></ref><ref id="r9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heller</surname><given-names>AR</given-names></name><name><surname>R&#x000f6;ssler</surname><given-names>S</given-names></name><name><surname>Litz</surname><given-names>RJ</given-names></name><name><surname>Stehr</surname><given-names>SN</given-names></name><name><surname>Heller</surname><given-names>SC</given-names></name><name><surname>Koch</surname><given-names>R</given-names></name><name><surname>Koch</surname><given-names>T</given-names></name></person-group><article-title>Omega-3 fatty acids improve the diagnosis-related clinical
outcome</article-title><source>Crit Care Med</source><month>4</month><year>2006</year><volume>34</volume><issue>4</issue><fpage>972</fpage><lpage>979</lpage><pub-id pub-id-type="pmid">16484909</pub-id></element-citation></ref><ref id="r10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waitzberg</surname><given-names>DL</given-names></name><name><surname>Torrinhas</surname><given-names>RS</given-names></name></person-group><article-title>Fish oil lipid emulsions and immune response: what clinicians
need to know</article-title><source>Nutr Clin Pract</source><season>Aug-Sep</season><year>2009</year><volume>24</volume><issue>4</issue><fpage>487</fpage><lpage>499</lpage><pub-id pub-id-type="doi">10.1177/0884533609339071</pub-id><pub-id pub-id-type="pmid">19605803</pub-id></element-citation></ref><ref id="r11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Berger</surname><given-names>MM</given-names></name><name><surname>Delodder</surname><given-names>F</given-names></name><name><surname>Liaudet</surname><given-names>L</given-names></name><name><surname>Tozzi</surname><given-names>P</given-names></name><name><surname>Schlaepfer</surname><given-names>J</given-names></name><name><surname>Chiolero</surname><given-names>RL</given-names></name><name><surname>Tappy</surname><given-names>L</given-names></name></person-group><article-title>Three short perioperative infusions of n-3 PUFAs reduce systemic
inflammation induced by cardiopulmonary bypass surgery: a randomized
controlled trial</article-title><source>Am J Clin Nutr</source><month>2</month><year>2013</year><volume>97</volume><issue>2</issue><fpage>246</fpage><lpage>254</lpage><pub-id pub-id-type="doi">10.3945/ajcn.112.046573</pub-id><pub-id pub-id-type="pmid">23269816</pub-id></element-citation></ref><ref id="r12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Langlois</surname><given-names>PL</given-names></name><name><surname>Hardy</surname><given-names>G</given-names></name><name><surname>Manzanares</surname><given-names>W</given-names></name></person-group><article-title>Omega-3 polyunsaturated fatty acids in cardiac surgery patients:
An updated systematic review and meta-analysis</article-title><source>Clin Nutr</source><month>6</month><year>2017</year><volume>36</volume><issue>3</issue><fpage>737</fpage><lpage>746</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2016.05.013</pub-id><pub-id pub-id-type="pmid">27293143</pub-id></element-citation></ref><ref id="r13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yadava</surname><given-names>M</given-names></name><name><surname>Hughey</surname><given-names>AB</given-names></name><name><surname>Crawford</surname><given-names>TC</given-names></name></person-group><article-title>Postoperative Atrial Fibrillation: Incidence, Mechanisms, and
Clinical Correlates</article-title><source>Heart Fail Clin</source><month>4</month><year>2016</year><volume>12</volume><issue>2</issue><fpage>299</fpage><lpage>308</lpage><pub-id pub-id-type="doi">10.1016/j.hfc.2015.08.023</pub-id><pub-id pub-id-type="pmid">26968672</pub-id></element-citation></ref><ref id="r14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feguri</surname><given-names>GR</given-names></name><name><surname>de Lima</surname><given-names>PRL</given-names></name><name><surname>de Cerqueira Borges</surname><given-names>D</given-names></name><name><surname>Toledo</surname><given-names>LR</given-names></name><name><surname>Batista</surname><given-names>LN</given-names></name><name><surname>E Silva</surname><given-names>TC</given-names></name><name><surname>Segri</surname><given-names>NJ</given-names></name><name><surname>de Aguilar-Nascimento</surname><given-names>JE</given-names></name></person-group><article-title>Preoperative carbohydrate load and intraoperatively infused
omega-3 polyunsaturated fatty acids positively impact nosocomial morbidity
after coronary artery bypass grafting: a double-blind controlled randomized
trial</article-title><source>Nutr J</source><day>20</day><month>4</month><year>2017</year><volume>16</volume><issue>1</issue><fpage>24</fpage><lpage>24</lpage><pub-id pub-id-type="doi">10.1186/s12937-017-0245-6</pub-id><pub-id pub-id-type="pmid">28427403</pub-id></element-citation></ref><ref id="r15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Breuer</surname><given-names>JP</given-names></name><name><surname>von Dossow</surname><given-names>V</given-names></name><name><surname>von Heymann</surname><given-names>C</given-names></name><name><surname>Griesbach</surname><given-names>M</given-names></name><name><surname>von Schickfus</surname><given-names>M</given-names></name><name><surname>Mackh</surname><given-names>E</given-names></name><name><surname>Hacker</surname><given-names>C</given-names></name><name><surname>Elgeti</surname><given-names>U</given-names></name><name><surname>Konertz</surname><given-names>W</given-names></name><name><surname>Wernecke</surname><given-names>KD</given-names></name><name><surname>Spies</surname><given-names>CD</given-names></name></person-group><article-title>Preoperative oral carbohydrate administration to ASA III-IV
patients undergoing elective cardiac surgery</article-title><source>Anesth Analg</source><month>11</month><year>2006</year><volume>103</volume><issue>5</issue><fpage>1099</fpage><lpage>1108</lpage><pub-id pub-id-type="pmid">17056939</pub-id></element-citation></ref><ref id="r16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feguri</surname><given-names>GR</given-names></name><name><surname>Lima</surname><given-names>PR</given-names></name><name><surname>Lopes</surname><given-names>AM</given-names></name><name><surname>Roledo</surname><given-names>A</given-names></name><name><surname>Marchese</surname><given-names>M</given-names></name><name><surname>Trevisan</surname><given-names>M</given-names></name><name><surname>Ahmad</surname><given-names>H</given-names></name><name><surname>Freitas</surname><given-names>BB</given-names></name><name><surname>Aguilar-Nascimento</surname><given-names>JE</given-names></name></person-group><article-title>Clinical and metabolic results of fasting abbreviation with
carbohydrates in coronary artery bypass graft surgery</article-title><source>Rev Bras Cir Cardiovasc</source><season>Jan-Mar</season><year>2012</year><volume>27</volume><issue>1</issue><fpage>7</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">22729296</pub-id></element-citation></ref><ref id="r17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>American Society of Anesthesiologists Committee</collab></person-group><article-title>Practice guidelines for preoperative fasting and the use of
pharmacologic agents to reduce the risk of pulmonary aspiration: application
to healthy patients undergoing elective procedures: an updated report by the
American Society of Anesthesiologists Committee on Standards and Practice
Parameters</article-title><source>Anesthesiology</source><month>3</month><year>2011</year><volume>114</volume><issue>3</issue><fpage>495</fpage><lpage>511</lpage><pub-id pub-id-type="doi">10.1097/ALN.0b013e3181fcbfd9</pub-id><pub-id pub-id-type="pmid">21307770</pub-id></element-citation></ref><ref id="r18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wahr</surname><given-names>JA</given-names></name><name><surname>Prager</surname><given-names>RL</given-names></name><name><surname>Abernathy 3rd</surname><given-names>JH</given-names></name><name><surname>Martinez</surname><given-names>EA</given-names></name><name><surname>Salas</surname><given-names>E</given-names></name><name><surname>Seifert</surname><given-names>PC</given-names></name><name><surname>Groom</surname><given-names>RC</given-names></name><name><surname>Spiess</surname><given-names>BD</given-names></name><name><surname>Searles</surname><given-names>BE</given-names></name><name><surname>Sundt 3rd</surname><given-names>TM</given-names></name><name><surname>Sanchez</surname><given-names>JA</given-names></name><name><surname>Shappell</surname><given-names>SA</given-names></name><name><surname>Culig</surname><given-names>MH</given-names></name><name><surname>Lazzara</surname><given-names>EH</given-names></name><name><surname>Fitzgerald</surname><given-names>DC</given-names></name><name><surname>Thourani</surname><given-names>VH</given-names></name><name><surname>Eghtesady</surname><given-names>P</given-names></name><name><surname>Ikonomidis</surname><given-names>JS</given-names></name><name><surname>England</surname><given-names>MR</given-names></name><name><surname>Sellke</surname><given-names>FW</given-names></name><name><surname>Nussmeier</surname><given-names>NA</given-names></name><collab>American Heart Association Council on Cardiovascular Surgery and
Anesthesia.Council on Cardiovascular and Stroke Nursing.and Council on
Quality of Care and Outcomes Research</collab></person-group><article-title>Patient safety in the cardiac operating room: human factors and
teamwork: a scientific statement from the American Heart
Association</article-title><source>Circulation</source><day>03</day><month>9</month><year>2013</year><volume>128</volume><issue>10</issue><fpage>1139</fpage><lpage>1169</lpage><pub-id pub-id-type="doi">10.1161/CIR.0b013e3182a38efa</pub-id><pub-id pub-id-type="pmid">23918255</pub-id></element-citation></ref><ref id="r19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abu Daya</surname><given-names>H</given-names></name><name><surname>Hage</surname><given-names>FG</given-names></name></person-group><article-title>Guidelines in review: ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017
appropriate use criteria for coronary revascularization in patients with
stable ischemic heart disease</article-title><source>J Nucl Cardiol</source><month>10</month><year>2017</year><volume>24</volume><issue>5</issue><fpage>1793</fpage><lpage>1799</lpage><pub-id pub-id-type="doi">10.1007/s12350-017-1017-6</pub-id><pub-id pub-id-type="pmid">28836156</pub-id></element-citation></ref><ref id="r20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murad</surname><given-names>H</given-names></name><name><surname>Murad</surname><given-names>FF</given-names></name></person-group><article-title>Controle de qualidade em cirurgia cardiovascular: um paradigma a
ser atingido</article-title><source>Rev Bras Cir Cardiovasc</source><year>2007</year><volume>29</volume><issue>1</issue><fpage>22</fpage><lpage>28</lpage></element-citation></ref><ref id="r21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Atik</surname><given-names>FA</given-names></name><name><surname>Garcia</surname><given-names>MF</given-names></name><name><surname>Santos</surname><given-names>LM</given-names></name><name><surname>Chaves</surname><given-names>RB</given-names></name><name><surname>Faber</surname><given-names>CN</given-names></name><name><surname>Corso</surname><given-names>RB</given-names></name><etal/></person-group><article-title>Resultados da implementa&#x000e7;&#x000e3;o de modelo
organizacional de um servi&#x000e7;o de cirurgia
cardiovascular</article-title><source>Rev Bras Cir Cardiovasc</source><comment>[Internet]</comment><month>6</month><year>2009</year><date-in-citation content-type="access-date">2019 Feb 09</date-in-citation><volume>24</volume><issue>2</issue><fpage>116</fpage><lpage>125</lpage><comment>Available from: </comment><pub-id pub-id-type="doi">10.1590/S0102-76382009000200005</pub-id><pub-id pub-id-type="pmid">19768288</pub-id></element-citation></ref><ref id="r22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeansen</surname><given-names>S</given-names></name><name><surname>Witkamp</surname><given-names>RF</given-names></name><name><surname>Garthoff</surname><given-names>JA</given-names></name><name><surname>van Helvoort</surname><given-names>A</given-names></name><name><surname>Calder</surname><given-names>PC</given-names></name></person-group><article-title>Fish oil LC-PUFAs do not affect blood coagulation parameters and
bleeding manifestations: Analysis of 8 clinical studies with selected
patient groups on omega-3-enriched medical nutrition</article-title><source>Clin Nutr</source><month>6</month><year>2018</year><volume>37</volume><issue>3</issue><fpage>948</fpage><lpage>957</lpage><pub-id pub-id-type="doi">10.1016/j.clnu.2017.03.027</pub-id><pub-id pub-id-type="pmid">28427779</pub-id></element-citation></ref><ref id="r23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>I</given-names></name><name><surname>Kranke</surname><given-names>P</given-names></name><name><surname>Murat</surname><given-names>I</given-names></name><name><surname>Smith</surname><given-names>A</given-names></name><name><surname>O'Sullivan</surname><given-names>G</given-names></name><name><surname>S&#x000f8;reide</surname><given-names>E</given-names></name><name><surname>Spies</surname><given-names>C</given-names></name><name><surname>in't Veld</surname><given-names>B</given-names></name><collab>European Society of Anaesthesiology</collab></person-group><article-title>Perioperative fasting in adults and children: guidelines from the
European Society of Anaesthesiology</article-title><source>Eur J Anaesthesiol</source><month>8</month><year>2011</year><volume>28</volume><issue>8</issue><fpage>556</fpage><lpage>569</lpage><pub-id pub-id-type="doi">10.1097/EJA.0b013e3283495ba1</pub-id><pub-id pub-id-type="pmid">21712716</pub-id></element-citation></ref><ref id="r24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furnary</surname><given-names>AP</given-names></name><name><surname>Gao</surname><given-names>G</given-names></name><name><surname>Grunkemeier</surname><given-names>GL</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zerr</surname><given-names>KJ</given-names></name><name><surname>Bookin</surname><given-names>SO</given-names></name><name><surname>Floten</surname><given-names>HS</given-names></name><name><surname>Starr</surname><given-names>A</given-names></name></person-group><article-title>Continuous insulin infusion reduces mortality in patients with
diabetes undergoing coronary artery bypass grafting</article-title><source>J Thorac Cardiovasc Surg</source><month>5</month><year>2003</year><volume>125</volume><issue>5</issue><fpage>1007</fpage><lpage>1021</lpage><pub-id pub-id-type="pmid">12771873</pub-id></element-citation></ref><ref id="r25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Furnary</surname><given-names>AP</given-names></name><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Bookin</surname><given-names>SO</given-names></name></person-group><article-title>Effect of hyperglycemia and continuous intravenous insulin
infusions on outcomes of cardiac surgical procedures: the Portland Diabetic
Project</article-title><source>Endocr Pract</source><season>Mar-Apr</season><year>2004</year><volume>10</volume><issue>Suppl 2</issue><fpage>21</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">15251637</pub-id></element-citation></ref><ref id="r26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>J&#x000e4;rvel&#x000e4;</surname><given-names>KM</given-names></name><name><surname>Khan</surname><given-names>NK</given-names></name><name><surname>Loisa</surname><given-names>EL</given-names></name><name><surname>Sutinen</surname><given-names>JA</given-names></name><name><surname>Laurikka</surname><given-names>JO</given-names></name><name><surname>Khan</surname><given-names>JA</given-names></name></person-group><article-title>Hyperglycemic Episodes Are Associated With Postoperative
Infections After Cardiac Surgery</article-title><source>Scand J Surg</source><month>6</month><year>2018</year><volume>107</volume><issue>2</issue><fpage>138</fpage><lpage>144</lpage><pub-id pub-id-type="doi">10.1177/1457496917731190</pub-id><pub-id pub-id-type="pmid">28934890</pub-id></element-citation></ref><ref id="r27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Van den Berghe</surname><given-names>G</given-names></name><name><surname>Wouters</surname><given-names>PJ</given-names></name><name><surname>Bouillon</surname><given-names>R</given-names></name><name><surname>Weekers</surname><given-names>F</given-names></name><name><surname>Verwaest</surname><given-names>C</given-names></name><name><surname>Schetz</surname><given-names>M</given-names></name><name><surname>Vlasselaers</surname><given-names>D</given-names></name><name><surname>Ferdinande</surname><given-names>P</given-names></name><name><surname>Lauwers</surname><given-names>P</given-names></name></person-group><article-title>Outcome benefit of intensive insulin therapy in the critically
ill: Insulin dose versus glycemic control</article-title><source>Crit Care Med</source><month>2</month><year>2003</year><volume>31</volume><issue>2</issue><fpage>359</fpage><lpage>366</lpage><pub-id pub-id-type="pmid">12576937</pub-id></element-citation></ref><ref id="r28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Thiessen</surname><given-names>S</given-names></name><name><surname>Vanhorebeek</surname><given-names>I</given-names></name><name><surname>Van den Berghe</surname><given-names>G</given-names></name></person-group><article-title>Glycemic control and outcome related to cardiopulmonary
bypass</article-title><source>Best Pract Res Clin Anaesthesiol</source><month>6</month><year>2015</year><volume>29</volume><issue>2</issue><fpage>177</fpage><lpage>187</lpage><pub-id pub-id-type="doi">10.1016/j.bpa.2015.03.003</pub-id><pub-id pub-id-type="pmid">26060029</pub-id></element-citation></ref><ref id="r29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamada</surname><given-names>T</given-names></name><name><surname>Shojima</surname><given-names>N</given-names></name><name><surname>Noma</surname><given-names>H</given-names></name><name><surname>Yamauchi</surname><given-names>T</given-names></name><name><surname>Kadowaki</surname><given-names>T</given-names></name></person-group><article-title>Glycemic control, mortality, and hypoglycemia in critically ill
patients: a systematic review and network meta-analysis of randomized
controlled trials</article-title><source>Intensive Care Med</source><month>1</month><year>2017</year><volume>43</volume><issue>1</issue><fpage>1</fpage><lpage>15</lpage><pub-id pub-id-type="doi">10.1007/s00134-016-4523-0</pub-id><pub-id pub-id-type="pmid">27637719</pub-id></element-citation></ref><ref id="r30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sz&#x000e9;kely</surname><given-names>A</given-names></name><name><surname>Levin</surname><given-names>J</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Tudor</surname><given-names>IC</given-names></name><name><surname>Vuylsteke</surname><given-names>A</given-names></name><name><surname>Ofner</surname><given-names>P</given-names></name><name><surname>Mangano</surname><given-names>DT</given-names></name><collab>Investigators of the Multicenter Study of Perioperative Ischemia
Research Group and the Ischemia Research and Education
Foundation</collab></person-group><article-title>Impact of hyperglycemia on perioperative mortality after coronary
artery bypass graft surgery</article-title><source>J Thorac Cardiovasc Surg</source><month>8</month><year>2011</year><volume>142</volume><issue>2</issue><fpage>430</fpage><lpage>7.e1</lpage><pub-id pub-id-type="doi">10.1016/j.jtcvs.2011.03.009</pub-id><pub-id pub-id-type="pmid">21497835</pub-id></element-citation></ref><ref id="r31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Knapik</surname><given-names>P</given-names></name><name><surname>Nadziakiewicz</surname><given-names>P</given-names></name><name><surname>Urbanska</surname><given-names>E</given-names></name><name><surname>Saucha</surname><given-names>W</given-names></name><name><surname>Herdynska</surname><given-names>M</given-names></name><name><surname>Zembala</surname><given-names>M</given-names></name></person-group><article-title>Cardiopulmonary bypass increases postoperative glycemia and
insulin consumption after coronary surgery</article-title><source>Ann Thorac Surg</source><month>6</month><year>2009</year><volume>87</volume><issue>6</issue><fpage>1859</fpage><lpage>1865</lpage><pub-id pub-id-type="doi">10.1016/j.athoracsur.2009.02.066</pub-id><pub-id pub-id-type="pmid">19463610</pub-id></element-citation></ref><ref id="r32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baker</surname><given-names>WL</given-names></name><name><surname>White</surname><given-names>CM</given-names></name><name><surname>Coleman</surname><given-names>CI</given-names></name></person-group><article-title>Letter by Baker et al regarding article, "benefits and risks of
corticosteroid prophylaxis in adult cardiac surgery: a dose-response
meta-analysis"</article-title><source>Circulation</source><day>17</day><month>11</month><year>2009</year><volume>120</volume><issue>20</issue><elocation-id>e163</elocation-id><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.872242</pub-id><pub-id pub-id-type="pmid">19917892</pub-id></element-citation></ref><ref id="r33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sousa-Uva</surname><given-names>M</given-names></name><name><surname>Milojevic</surname><given-names>M</given-names></name><name><surname>Head</surname><given-names>SJ</given-names></name><name><surname>Jeppsson</surname><given-names>A</given-names></name></person-group><article-title>The 2017 EACTS guidelines on perioperative medication in adult
cardiac surgery and patient blood management</article-title><source>Eur J Cardiothorac Surg</source><day>01</day><month>1</month><year>2018</year><volume>53</volume><issue>1</issue><fpage>1</fpage><lpage>2</lpage><pub-id pub-id-type="doi">10.1093/ejcts/ezx448</pub-id><pub-id pub-id-type="pmid">29240913</pub-id></element-citation></ref><ref id="r34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pradelli</surname><given-names>L</given-names></name><name><surname>Mayer</surname><given-names>K</given-names></name><name><surname>Muscaritoli</surname><given-names>M</given-names></name><name><surname>Heller</surname><given-names>AR</given-names></name></person-group><article-title>n-3 fatty acid-enriched parenteral nutrition regimens in elective
surgical and ICU patients: a meta-analysis</article-title><source>Crit Care</source><day>04</day><month>10</month><year>2012</year><volume>16</volume><issue>5</issue><fpage>R184</fpage><lpage>R184</lpage><pub-id pub-id-type="doi">10.1186/cc11668</pub-id><pub-id pub-id-type="pmid">23036226</pub-id></element-citation></ref><ref id="r35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Macchia</surname><given-names>A</given-names></name><name><surname>Levantesi</surname><given-names>G</given-names></name><name><surname>Franzosi</surname><given-names>MG</given-names></name><name><surname>Geraci</surname><given-names>E</given-names></name><name><surname>Maggioni</surname><given-names>AP</given-names></name><name><surname>Marfisi</surname><given-names>R</given-names></name><name><surname>Nicolosi</surname><given-names>GL</given-names></name><name><surname>Schweiger</surname><given-names>C</given-names></name><name><surname>Tavazzi</surname><given-names>L</given-names></name><name><surname>Tognoni</surname><given-names>G</given-names></name><name><surname>Valagussa</surname><given-names>F</given-names></name><name><surname>Marchioli</surname><given-names>R</given-names></name><collab>GISSI-Prevenzione Investigators</collab></person-group><article-title>Left ventricular systolic dysfunction, total mortality, and
sudden death in patients with myocardial infarction treated with n-3
polyunsaturated fatty acids</article-title><source>Eur J Heart Fail</source><month>8</month><year>2005</year><volume>7</volume><issue>5</issue><fpage>904</fpage><lpage>909</lpage><pub-id pub-id-type="pmid">16087142</pub-id></element-citation></ref><ref id="r36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mozaffarian</surname><given-names>D</given-names></name><name><surname>Geelen</surname><given-names>A</given-names></name><name><surname>Brouwer</surname><given-names>IA</given-names></name><name><surname>Geleijnse</surname><given-names>JM</given-names></name><name><surname>Zock</surname><given-names>PL</given-names></name><name><surname>Katan</surname><given-names>MB</given-names></name></person-group><article-title>Effect of fish oil on heart rate in humans: a meta-analysis of
randomized controlled trials</article-title><source>Circulation</source><day>27</day><month>9</month><year>2005</year><volume>112</volume><issue>13</issue><fpage>1945</fpage><lpage>1952</lpage><pub-id pub-id-type="pmid">16172267</pub-id></element-citation></ref><ref id="r37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><collab>Risk and Prevention Study Collaborative Group</collab><name><surname>Roncaglioni</surname><given-names>MC</given-names></name><name><surname>Tombesi</surname><given-names>M</given-names></name><name><surname>Avanzini</surname><given-names>F</given-names></name><name><surname>Barlera</surname><given-names>S</given-names></name><name><surname>Caimi</surname><given-names>V</given-names></name><name><surname>Longoni</surname><given-names>P</given-names></name><name><surname>Marzona</surname><given-names>I</given-names></name><name><surname>Milani</surname><given-names>V</given-names></name><name><surname>Silletta</surname><given-names>MG</given-names></name><name><surname>Tognoni</surname><given-names>G</given-names></name><name><surname>Marchioli</surname><given-names>R</given-names></name></person-group><article-title>n-3 fatty acids in patients with multiple cardiovascular risk
factors</article-title><source>N Engl J Med</source><day>09</day><month>5</month><year>2013</year><volume>368</volume><issue>19</issue><fpage>1800</fpage><lpage>1808</lpage><pub-id pub-id-type="doi">10.1056/NEJMoa1205409</pub-id><comment>Erratum in: N Engl J Med. 2013 May 30;368(22):2146</comment><pub-id pub-id-type="pmid">23656645</pub-id></element-citation></ref></ref-list></back></article>